NewAmsterdam Pharma Co N.V.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

NAMS$19.18+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For the three months ended June 30,		For the six months ended June 30,
	2026	2025	2026	2025
(In thousands of USD, except per share amounts)
Revenue	3,701	19,145	6,741	22,123
Operating expenses:
Research and development expenses	41,673	27,516	79,682	72,267
Selling, general and administrative expenses	26,892	27,264	50,343	54,416
Total operating expenses	68,565	54,780	130,025	126,683
Operating loss	(64,864)	(35,635)	(123,284)	(104,560)
Other income (expense):
Interest income	5,810	7,055	11,460	14,406
Fair value change – earnout	—	—	—	3,992
Fair value change – warrants	(4,555)	2,590	1,387	16,352
Foreign exchange gains/(losses)	(526)	8,626	(2,139)	12,919
Loss before tax	(64,135)	(17,364)	(112,576)	(56,891)
Income tax expense	—	—	—	—
Loss for the period	(64,135)	(17,364)	(112,576)	(56,891)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax	(360)	(107)	(932)	(140)
Total comprehensive loss for the period, net of tax	(64,495)	(17,471)	(113,508)	(57,031)
Net loss per ordinary share
Basic and diluted	$(0.52)	$(0.15)	$(0.92)	$(0.48)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.